The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today

vivax malaria

Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders

March 24, 2021 - 14:50 -- Open Access
Author(s): 
Bipin Adhikari, Ghulam Rhahim Awab and Lorenz von Seidlein
Reference: 
Malaria Journal 2021 20:164, 23 March 2021

Wide-spread implementation of treatment regimens for the radical cure of vivax malaria is hindered by a range of factors. This has resulted in an increase in the relative proportion of vivax malaria and is an important obstacle in the achievement of global malaria elimination by 2030. The main objective of this study was to explore the current policies guiding the treatment plans on vivax malaria, and the factors affecting the implementation of radical cure in South/South East Asian and Asian Pacific countries.

The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China

March 24, 2021 - 14:40 -- Open Access
Author(s): 
Herong Huang, Ying Dong, Yanchun Xu, Yan Deng, Canglin Zhang, Shuping Liu, Mengni Chen and Yan Liu
Reference: 
Malaria Journal 2021 20:160, 20 March 2021

Accumulating evidence suggest that compromised CYP2D6 enzyme activity caused by gene mutation could contribute to primaquine failure for the radical cure of vivax malaria. The current study aims to preliminarily reveal the association between the recurrence of vivax malaria in Yunnan Province and CYP2D6 gene mutation by analysing polymorphisms in the entire coding region of human CYP2D6 gene.

Performance of a sensitive haemozoin‐based malaria diagnostic test validated for vivax malaria diagnosis in Brazilian Amazon

March 18, 2021 - 09:14 -- Open Access
Author(s): 
Gisely Cardoso de Melo, Rebeca Linhares Abreu Netto, Marcus Vinícius Guimarães Lacerda, et al.
Reference: 
Malaria Journal 2021 20:146, 12 March 2021

Vivax malaria diagnosis remains a challenge in malaria elimination, with current point of care rapid diagnostic tests (RDT) missing many clinically significant infections because of usually lower peripheral parasitaemia. Haemozoin-detecting assays have been suggested as an alternative to immunoassay platforms but to date have not reached successful field deployment. Haemozoin is a paramagnetic crystal by-product of haemoglobin digestion by malaria parasites and is present in the food vacuole of malaria parasite-infected erythrocytes. This study aimed to compare the diagnostic capability of a new haemozoin-detecting platform, the Gazelle™ device with optical microscopy, RDT and PCR in a vivax malaria-endemic region.

New laboratory perspectives for evaluation of vivax malaria infected patients: a useful tool for infection monitoring

April 27, 2020 - 14:10 -- Open Access
Author(s): 
Alves-Junior ER, Gomes LT, Dombroski TCD, Nery AF, Filho SV, Nakazato L, Fontes CJF, Rios-Santos F
Reference: 
Braz J Infect Dis. 2020 Apr 23. pii: S1413-8670(20)30027-1

In recent years, the number of cases with severe Plasmodium vivax malaria has shown an increasing trend. It is, therefore, important to identify routine laboratory markers that best characterize the acute disease phase and can serve as a tool for clinical follow-up of patients. In a cohort study, we followed 87 patients with acute P. vivax monoinfection acquired in an endemic region of the Brazilian Amazon. Forty-two different biochemical and hematological parameters frequently tested in clinical routine were evaluated at the acute phase and the convalescent phase.

NOT Open Access | Main B‐cell epitopes of PvAMA‐1 and PvMSP‐9 are targeted by naturally acquired antibodies and epitope‐specific memory cells in acute and convalescent phases of vivax malaria

April 20, 2020 - 08:54 -- NOT Open Access
Author(s): 
Roberta Reis Soares, Clovis Ryuichi Nakaie, Rodrigo Nunes Rodrigues‐da‐Silva, Rogério Lauria da Silva, Josué da Costa Lima‐Junior, Kézia Katiani Gorza Scopel
Reference: 
Parasite Immunology, Volume42, Issue5, May 2020 e12705

Although antibodies are considered critical for malaria protection, little is known about the mechanisms/factors that maintain humoral immunity, especially regarding the induction and maintenance of memory B cells over time. In Brazilian endemic areas, this is the first time that the profile of antibody responses and the occurrence of antigen‐specific memory B cells (MBC) against P vivax were investigated during acute malaria and up to six months after parasite clearance.

NOT Open Access | Main B-cell epitopes of PvAMA-1 and PvMSP-9 are targeted by naturally acquired antibodies and epitope-specific memory cells in acute and convalescent phases of vivax malaria

March 2, 2020 - 15:13 -- NOT Open Access
Author(s): 
Soares RR, Nakaie CR, Rodrigues-da-Silva RN, da Silva RL, da Costa Lima-Junior J, Scopel KKG
Reference: 
Parasite Immunol. 2020 Feb 24:e12705

Although antibodies are considered critical for malaria protection, little is known about the mechanisms/factors that maintain humoral immunity, especially regarding the induction and maintenance of memory B cells over time. In Brazilian endemic areas, this is the first time that the profile of antibody responses and the occurrence of antigen‐specific memory B‐cells (MBC) against P. vivax were investigated during acute malaria and up to six months after parasite clearance.

Singultus as an Unusual Debut of Plasmodium vivax Malaria

November 19, 2019 - 15:14 -- Open Access
Author(s): 
Guadarrama-Conzuelo F, Saad Manzanera AD.
Reference: 
Cureus. 2019 Sep 1;11(9):e5548.

We describe this previously unreported association, hypothesize on the potential mechanism and review the literature on singultus and unusual presentations of Plasmodium infections.

Misperceptions of patients and health workers regarding malaria elimination in the Brazilian Amazon: a qualitative study

July 8, 2019 - 16:58 -- Open Access
Author(s): 
Felipe Leão Gomes Murta, Maxwell Oliveira Mendes, Vanderson Souza Sampaio, Abrahim Sena Baze Junior, Ximena Pamela Díaz-Bermúdez, Wuelton Marcelo Monteiro and Marcus Vinícius Guimarães Lacerda
Reference: 
Malaria Journal 2019 18:223, 4 July 2019

Brazil has considerably reduced the number of cases of malaria in recent years and aims to eradicate the disease completely, however, vivax malaria continues to be a major challenge for the health system. In this context, the key to building a successful elimination programme may lie in the knowledge and the perceptions of the health agents, the patients affected by the disease and the personnel responsible for malaria diagnosis, treatment and control at the local level.

Factors associated with children’s health facility visits for primaquine treatment in rural Papua New Guinea

February 21, 2019 - 16:30 -- Open Access
Author(s): 
Akiko Yoshii, Makoto Sekihara, Takuro Furusawa, Francis Hombhanje and Takahiro Tsukahara
Reference: 
Malaria Journal 2019 18:42, 20 February 2019

Few children received PQ treatment during the second visit to HFs following diagnosis of potential non-falciparum malaria.

Medical Treatment: 

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

November 15, 2018 - 15:00 -- Open Access
Author(s): 
Sara Avalos, Rosa E. Mejia, Gustavo Fontecha, et al.
Reference: 
Malaria Journal 2018 17:415

The findings support that the intake of PQ during 14 days of treatment against vivax malaria is safe in patients with a class III variant of G6PDd. In view of the new national regulations in the shortened treatment of vivax malaria for 7 days, it is advisable to be alert of potential cases of severe haemolysis that could occur among G6PD deficient hemizygous males with a class II mutation such as the Santamaria variant, previously reported in the country.

Pages

Subscribe to RSS - vivax malaria